Compare TRDA & STRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | STRT |
|---|---|---|
| Founded | 2016 | 1908 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.4M | 331.1M |
| IPO Year | 2021 | 1995 |
| Metric | TRDA | STRT |
|---|---|---|
| Price | $10.88 | $90.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 246.9K | 42.6K |
| Earning Date | 03-06-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.90 |
| EPS | N/A | ★ 6.59 |
| Revenue | $61,520,000.00 | ★ $586,028,000.00 |
| Revenue This Year | N/A | $4.15 |
| Revenue Next Year | $21.02 | $4.12 |
| P/E Ratio | ★ N/A | $13.23 |
| Revenue Growth | N/A | ★ 6.01 |
| 52 Week Low | $4.93 | $31.57 |
| 52 Week High | $13.82 | $92.50 |
| Indicator | TRDA | STRT |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 58.47 |
| Support Level | $10.48 | $86.19 |
| Resistance Level | $11.41 | $92.50 |
| Average True Range (ATR) | 0.74 | 4.44 |
| MACD | -0.06 | 0.41 |
| Stochastic Oscillator | 54.08 | 72.11 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Strattec Security Corp designs develops, manufactures, and markets mechanical locks, electronically enhanced locks, and keys. It also produces ignition lock housings; and access control products, including latches, power sliding door systems, and door handles. Strattec ships products to customer locations in the United States, Canada, Mexico, Europe, South America, Korea, and China, and provides full-service aftermarket support. Strattec also supplies products for the heavy truck and recreational vehicle markets, as well as precision, die castings.